Skip to Content

Daklinza (daclatasvir) Disease Interactions

There is 1 disease interaction with Daklinza (daclatasvir):


Daclatasvir (Includes Daklinza) ↔ reactivation HBV

Severe Potential Hazard, Moderate plausibility. Applies to: Infectious Hepatitis

In hepatitis C virus (HCV)/hepatitis B virus (HBV) coinfected patients, the use of daclatasvir may cause a reactivation of the HBV. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. It is recommended to test all patients for evidence of prior HBV infection before initiating therapy with daclatasvir. Close monitoring for signs and symptoms of hepatitis flare or HBV reactivation is recommended during HCV treatment with daclatasvir and during after treatment follow-up. Consider appropriate management for patients with HBV infection as clinically indicated.

Daklinza (daclatasvir) drug interactions

There are 204 drug interactions with Daklinza (daclatasvir)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.